{"filing":{"accession_number":"0001070081-26-000023","cik":"0001070081","ticker":"PTCT","company_name":"PTC THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"tmb-20260921x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/tmb-20260921x8k.htm"},"events":[{"id":34036,"run_id":31332,"accession_number":"0001070081-26-000023","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"PTC Therapeutics completed its acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics. The acquisition expands PTC's pipeline with a clinical-stage asset expected to have a BLA submission in Q4 2026.","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37657,"accession_number":"0001070081-26-000023","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"PTC Therapeutics completed the acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics. The press release explicitly states \"PTC Therapeutics, Inc. today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920.\" This is a material acquisition of a product candidate that expands PTC's pipeline and represents a significant strategic transaction requiring 8-K disclosure under Item 1.01 or 2.01 (though disclosed under Item 7.01 as a Regulation FD disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:38:11.844845+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37658,"accession_number":"0001070081-26-000023","item_number":"8.01","item_title":"Other Information.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"PTC Therapeutics completed the acquisition of ST-920, a BLA-stage gene therapy for Fabry disease, from Sangamo Therapeutics. The Item 8.01 disclosure and accompanying press release explicitly state \"PTC Completes Acquisition of ST-920\" and describe this as a \"previously announced agreement\" that has now been completed. This is a material acquisition of a clinical-stage asset that will be integrated into PTC's pipeline, with expected BLA submission in Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:38:11.844845+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37657,"accession_number":"0001070081-26-000023","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"PTC Therapeutics completed the acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics. The press release explicitly states \"PTC Therapeutics, Inc. today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920.\" This is a material acquisition of a product candidate that expands PTC's pipeline and represents a significant strategic transaction requiring 8-K disclosure under Item 1.01 or 2.01 (though disclosed under Item 7.01 as a Regulation FD disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:38:11.844845+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-09-21"},{"id":37658,"accession_number":"0001070081-26-000023","item_number":"8.01","item_title":"Other Information.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"PTC Therapeutics completed the acquisition of ST-920, a BLA-stage gene therapy for Fabry disease, from Sangamo Therapeutics. The Item 8.01 disclosure and accompanying press release explicitly state \"PTC Completes Acquisition of ST-920\" and describe this as a \"previously announced agreement\" that has now been completed. This is a material acquisition of a clinical-stage asset that will be integrated into PTC's pipeline, with expected BLA submission in Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:38:11.844845+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-09-21"}]}